Swiss drug major Roche and US life science company Entelos say that they have entered into a two-year R&D collaboration, which will focus on the field of metabolic disease. Under the terms of the deal, Entelos will conduct biosimulation research using its PhysioLab metabolism platform, with Roche agreeing to fund the work. The Basel-based firm will also make developmental milestone payments as metabolic pathways and biomarkers are identified.
Roche added that the approach used by Entelos, the assessment of a drug's impact on the metabolism of a "virtual patient," could prove useful in the analysis of preclinical and clinical data in the optimization of future work. Financial terms were not made public.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze